
United States · Research startup
Fountain Therapeutics is building a pipeline of therapeutics to treat age-related diseases by reversing cellular age.
Funding reportedLast round: Series A
Fountain Therapeutics is building a pipeline of therapeutics to treat age-related diseases by reversing cellular age.
The company has combined the expertise of leaders in aging research and computation to build an AI-driven platform that extracts previously hidden cellular features to measure aging with remarkable precision. Fountain is currently screening a large diversity of drug compounds, including small molecules and biologics, to identify novel drugs that specifically reverse the age of cells for the development of therapeutics to treat age-related diseases. Fountain is comprised of an exceptional growing team of scientists, engineers, physicians, drug hunters and developers, and entrepreneurs originating from top academic institutions, research laboratories and biotech companies in the world. The team is united by the common goal of building a new way forward to decouple aging from disease and improve the quality of life for our aging population. Fountain is based in South San Francisco, California. For more information on Fountain, please visit www.fountaintx.com.
Funding, as reported
From the SEC filings it signed: 2 on the team.
On the board, as filediAlex MorganAshish Khanna
What they build
Known for
health carehigh-content screeningin vitro screeningdisease pathwaysin vivo screeningphenotypic scoringbiotechnology researchmetabolic diseasescellular agingmedical researchdisease targetscirculating factorsmuscle atrophyphenotypic modelsmetabolic healthhigh-content analysis
Built with from their website
parallax.jsSquarespace ECommerceGoogle CloudGoogle WorkspaceViewport MetaGoogle Cloud HostingGoogle MeetPriority HintsMagento 2Mobile Friendly
Magento Open SourceOpen GraphSquarespaceHSTSGoogle Cloud DNSSquarespace CommerceCart FunctionalityAdobe Fonts
Add your raise, your deck and your story, and put Fountain Therapeutics in front of investors. Or tell us what we have wrong.